Clinical relevance of laboratory and animal data on tamoxifen

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 39-44

  Swenberg, James A ^a  

^a IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; BREAST CANCER; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DNA ADDUCT; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LIVER CANCER; NONHUMAN; RAT; RISK FACTOR; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENICITY TESTS; DNA; DNA ADDUCTS; HUMANS; LABORATORIES; TAMOXIFEN;

EID: 0030965052     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Kimmick G, Muss HB: Current status of endocrine therapy for metastatic breast cancer Oncology 9:877-890, 1995.
2. Jaiyesimi LA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13:513-529, 1995.
3. Robinson E, Kimmick GG, Muss HB: Tamoxifen in postmenopausal women: A safety perspective. Drugs & Aging 8:329-337, 1996.
4. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989.
5. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1:836-840, 1985.
6. McDonald CC, Stewart HJ, Scottish Breast Cancer Committee: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 303:435-437, 1991.
7. Rutqvist LE, Mattsson A, Stockholm Breast Cancer Study Group: Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85:1398-1406, 1993.
8. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-83, 1994.
9. Fisher B, Redmond CK: A clinical trial to determine the worth of tamoxifen for preventing breast cancer. National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol P-1, 1991.
10. Bilimoria MM, Assikis VJ, Jordan VC: Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2:140-150, 1996.
11. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994.
12. Ames BN, Gold LS: Chemical carcinogenesis: too many rodent carcinogens? Proc Natl Acad Sci 87:7772-7776, 1990.
13. Cunningham A, Klopman G, Rosenkranz HS: A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites. Mutation Res 349:85-94, 1996.
14. Osborne MR, Hewer A, Hardcastle IR, et al: Identification of the major tamoxifen-deoxyguanosme adduct formed in liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71, 1996.
15. Phillips DH, Carmichael PL, Hewer A, et al: α-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes Cancer Res 54:5518-5522, 1994
16. Moorthy B, Sriram P, Pathak DN, et al: Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal activation and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 56:53-57, 1996.
17. Potter GA, McCague R, Jarman M, et al: A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic metabolism. Carcinogenesis 15:439-442, 1994.
18. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15:2087-2094, 1994.
19. Pathak DN, Bodell WJ: DNA adduct formation by tamoxifen with rat and human liver microsomal activating systems. Carcinogenesis 15:529-532, 1994.
20. Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363, 1992.
21. Mühlemann K, Cook LS, Weiss NS: The incidence of hepatocellular carcinomain US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 30:201-204, 1994.
22. Vogelstein B, Kunzler KW: The multistep nature of cancer. Trends in Genetics 9:138-141, 1993.
23. Swenberg JA, Fedtke N, Fennell TR: Relationships between carcinogen exposure, DNA adducts and Carcinogenesis, in Clayson DB, Munro IC, Shubik P et al (eds): Progress in Predictive Toxicology, pp 161-184, Elsevier Science Publishers, 1990.
24. La DK, Swenberg JA: DNA adducts: Biological markers of exposure and potential applications to risk assessment. Mutat Res 365:129-146, 1996.
25. Phillips DH, Carmichael PL, Hewer A, et al: Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17:89-94, 1996
26. Mani C, Gelboin HV, Park SS, et al: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen: Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21:645-656, 1993.
27. Lim CK, Yuan Z-X, Lamb JH, et al: A comparative study of tamoxifen metabolism in the female rat, mouse and human liver microsomes. Carcinogenesis 15-5898-5893, 1994.
28. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995.
29. Phillips DH, Hewer A, Grover PL, et al: Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17:1149-1152, 1996.
30. Carmichael PL, Ugwumadu AHN, Neven P: Lack of genotoxicity of tamoxifen in human endometrium Cancer Res 56:1475-1479, 1996.
31. Hemminki K, Widlak P, Hou S-M: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16:1661-1664, 1995.
32. Pathak DN, Pongracz K, Bodell WJ: Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: Comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 17:1785-1790, 1996.
33. White INH, de Matteis F, Davies A, et al: Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203, 1992.
34. 32P-postlabeling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumor formation. Carcinogenesis 16:1299-1304, 1995.
35. Hemminki K, Rajaniemi H, Lindahl B, et al: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377, 1996.
36. Hirsimaki P, Hirsimaki Y, Nieminen L, et al: Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch Toxicol 67:49-54, 1993.
37. Williams GM, Iatropoulos MJ, Djordjevic MV, et al: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:3l5-317, 1993.
38. Greaves P, Goonelilleke R, Nunn G, et al: Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res 53:3919-3924, 1993.
39. Tucker MJ, Adam HK, Patterson JS: Tamoxifen, in Lawrence DR, McLean AEM, Weatherall M (eds): Safety Testing of New Drugs, pp 125-161, Orlando FL, Academic Press, 1984.
40. Coe JE, Ross MJ: Tamoxifen inhibits estrogen-induced hepatic injury in hamsters. Endocrinology 122:137-144, 1988.
41. Coe JE, Ishak KG, Ward JM, et al: Tamoxifen prevents induction of hepatic neoplasms by zeranol, an estrogenic food contaminant Proc Natl Acad Sci USA 89:1085-1089, 1992.
42. Dragan YP, Vaughan J, Jordan VC, Pitot HC: Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16:2733-2741, 1995.
43. Nestmann ER, Bryant DW, Carr CJ: Toxicological significance of DNA adducts: Summary of discussions with an expert panel. Regul Toxicol Pharmacol 24:9-18, 1996.